

CORRECTION

Open Access



Correction: Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer

Ning-Yuan Lee¹, Melissa Hum¹, Sabna Zihara¹, Lanying Wang², Matthew K. Myint¹, Darren Wan-Teck Lim^{2,3}, Chee-Keong Toh², Anders Skanderup⁴, Jens Samol^{5,6}, Min-Han Tan⁷, Peter Ang⁸, Soo-Chin Lee^{9,10}, Eng-Huat Tan^{2,11}, Gillianne G. Y. Lai^{2,3}, Daniel S. W. Tan^{2,3,4,11}, Yoon-Sim Yap^{2,3} and Ann S. G. Lee^{1,3,12*}

Correction: Human Genomics (2023) 17:66
<https://doi.org/10.1186/s40246-023-00510-7>

Following publication of the original article [1], the authors reported that some words in Table 1 were out of alignment and it needed to be corrected.

The correct Table 1 has been provided in this correction.

The original article [1] has been corrected.

The original article can be found online at <https://doi.org/10.1186/s40246-023-00510-7>.

*Correspondence:

Ann S. G. Lee
gmslimsg@nus.edu.sg

¹ Division of Cellular and Molecular Research, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore

² Division of Medical Oncology, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore

³ SingHealth Duke-NUS Oncology Academic Clinical Programme (ONCO ACP), Duke-NUS Medical School, 8 College Road, Singapore 169857, Singapore

⁴ Genome Institute of Singapore, 60 Biopolis St, Singapore 138672, Singapore

⁵ Medical Oncology Department, Tan Tock Seng Hospital, 11 Jalan Tan Tock Seng, Singapore 308433, Singapore

⁶ Johns Hopkins University, Baltimore, MD 21218, USA

⁷ Lucence Diagnostics Pte Ltd, 211 Henderson Road, Singapore 159552, Singapore

⁸ Oncocare Cancer Centre, Gleneagles Medical Centre, 6 Napier Road, Singapore 258499, Singapore

⁹ Department of Hematology-Oncology, National University Cancer Institute, Singapore (NCIS), National University Health System, 5 Lower Kent Ridge Road, Singapore 119074, Singapore

¹⁰ Cancer Science Institute, Singapore (CSI), National University of Singapore, 14 Medical Dr, Singapore 117599, Singapore

¹¹ Clinical Trials and Epidemiological Sciences, National Cancer Centre Singapore, 30 Hospital Boulevard, Singapore 168583, Singapore

¹² Department of Physiology, Yong Loo Lin School of Medicine, Medical Drive, National University of Singapore, Singapore 117593, Singapore



© The Author(s) 2023. **Open Access** This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>. The Creative Commons Public Domain Dedication waiver (<http://creativecommons.org/publicdomain/zero/1.0/>) applies to the data made available in this article, unless otherwise stated in a credit line to the data.

Table 1 Demographic and clinicopathological characteristics of patient cohort

Characteristics (n = 55)		n (%)	
Ethnicity			
Chinese		50 (90.9)	
Others		5 (9.1)	
Smoking status			
Never-smoker		52 (94.5)	
Smoker		3 (5.5)	
Temporal occurrence of lung and breast cancer diagnosis			
Lung cancer occurred first		5 (9.1)	
Breast cancer occurred first		38 (69.1)	
Synchronous (within 6 months)		12 (21.8)	
Family cancer history (any primary)			
First degree		27 (49.1)	
Second degree		4 (7.3)	
No known history		24 (43.6)	
Family history of breast and/or lung cancer			
First degree		8 (14.5)	
Second degree		2 (3.6)	
Breast cancer		Lung cancer	
Diagnosis year	1976–2018	Diagnosis year	2005–2018
Median age, years (range)	55 (34–81)	Median age, years (range)	65 (48–78)
Histology	n (%)	Histology	n (%)
Ductal carcinoma in situ (DCIS)	5 (9.1)	Adenocarcinoma (ADC)	44 (80)
Infiltrating ductal carcinoma (IDC)	33 (60)	Neuroendocrine carcinoma	
Infiltrating lobular carcinoma (ILC)	4 (7.3)	Carcinoid	2 (3.6)
DCIS + DCIS (bilateral)	1 (1.8)	SCLC	3 (5.5)
IDC + DCIS (bilateral)	2 (3.6)	Undifferentiated	1 (1.8)
IDC + ILC (bilateral)	2 (3.6)	Lymphoepithelioma-like carcinoma (LELC)	1 (1.8)
IDC + unknown subtype (bilateral)	1 (1.8)	ADC + carcinoid (bilateral, synchronous)	1 (1.8)
Mucinous adenocarcinoma	3 (5.5)	ADC + ADC (bilateral, synchronous)	1 (1.8)
Subtype not specified (NOS)	4 (7.3)	ADC + ADC (same side, synchronous)	2 (3.6)
Staging^a		Staging^b	
0	6 (10.9)	0	0 (0.0)
I/II	44 (80.0)	I/II	26 (47.3)
III	4 (7.3)	III	7 (12.7)
IV	1 (1.8)	IV	22 (40.0)
Hormone and HER2 status^c		EGFR status (adenocarcinoma only, n = 49)	
ER		Not tested	4 (8.2)
Positive	36 (65.4)	Tested	45 (91.8)
Negative	10 (18.2)	Mutant	33 (73.3*)
Not tested/unknown	9 (16.4)	Exon19 del	19 (57.6^)
PR		L858R	11 (33.3^)
Positive	30 (54.5)	Others	3 (9.1^)
Negative	15 (27.3)	Wild type	12 (26.7*)
Not tested/unknown	10 (18.2)		
HER2			
Positive	4 (7.3)		
Negative	28 (50.9)		
Not tested/unknown/equivocal	23 (41.8)		

Table 1 (continued)

^a For bilateral cancers, higher stage was taken

^b All 4 multi-lesion cases are stage I

^c For bilateral cancers, higher stage's status was presented

*Over tested cases (total n = 45)

^ Over mutant cases (total n = 33)

Published online: 14 August 2023

Reference

1. Lee NY, Hum M, Zihara S, et al. Landscape of germline pathogenic variants in patients with dual primary breast and lung cancer. *Hum Genomics*. 2023;17:66. <https://doi.org/10.1186/s40246-023-00510-7>.

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.